Incidence of Adverse Events Related to Therapies with sodium iodine (131I): Contribution to the Pharmacovigilance in Brazil
DOI:
https://doi.org/10.15392/2319-0612.2024.2481Keywords:
radioiodine therapy, adverse events, differentiated thyroid carcinomaAbstract
Radiopharmaceuticals for therapeutic have been increasingly used for the treatment of various pathologies. Beta-emitting radionuclides stand out in this modality due to the physical characteristics of the emitted particle. Iodine-131 (131I) is an example of a beta-emitting radionuclide, applied in the production of radiopharmaceuticals such as sodium iodine (131I), which represents an excellent therapeutic modality in the treatment of differentiated thyroid carcinomas. As well as other therapeutic modalities, radionuclide therapy using radiopharmaceuticals can also cause adverse reactions. This study aimed to evaluate the incidence of possible adverse events related to therapy with sodium iodine (131I), and evaluate the correlation with the administered activities, obtaining unprecedented pharmacovigilance data related to the use of therapeutic radiopharmaceuticals in Brazil. A retrospective analysis of medical records was carried out with electronic patients’ data diagnosed with differentiated thyroid carcinoma and undergoing therapy with radioiodine. A total of 116 patients were recovered from January/2019 to April/2021 and 89 were included according to the inclusion criteria. Of the patients, 54.6% reported an adverse event after radioiodine therapy. The most frequent events were those related to the gastrointestinal tract and local irradiation, and it was possible to identify that there was an increased incidence of events in those patients who were treated with greater activities. Based on the results obtained, the present study demonstrated the presence of acute events related to therapy in the studied population and that the incidence of events was correlated with the activity prescribed.
Downloads
References
SPEEDER, T. W. Targeted Radionuclide Therapy. Lippincott Willians & Wilkins, Philadelphia, 2011.
LUSTER, M.; PFESTROFF, A.; Radioiodine Therapy. Semin Nucl Med, v. 47, n. 2, p. 126-134, 2017. DOI: https://doi.org/10.1053/j.semnuclmed.2016.10.002
SIPOS, J.A.; MAZZAFERRI, E. L. Thyroid cancer epidemiology and prognostic variables. Clinical oncology (Royal College of Radiologists), v. 22, n. 6, p. 395- 404, 2010. DOI: https://doi.org/10.1016/j.clon.2010.05.004
MCLEOD, D. A. S.; SAWKA, A. M.; COOPER, D. S. Controversies in primary treatment of low -risk papillary thyroid cancer. The Lancet, v. 381, n. 1, p. 1046- 1057, 2013. DOI: https://doi.org/10.1016/S0140-6736(12)62205-3
CARBALLO, M.; RODERICK, M. Quiros To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients. Journal of Oncology. V. 4, p. 1-11, 2012. DOI: https://doi.org/10.1155/2012/707156
DEWARAJA, G. M.; FREY, E. C.; SGOUROS, G.; BRILL, A. B.; ROBERSON, P. Quantitative spect for patient-apecific 3-dimensional. Dosimetry in Internal Radionuclide Therapya, v. 53, n. 1, p. 1310-1325, 2012. DOI: https://doi.org/10.2967/jnumed.111.100123
ALVES, F.N.; GIORGIS, L.S.; ARAÚJO, E.B. Registro e Boas Práticas de Fabricação de Radiofármacos. Em: Vieira, F.P.; Rediguieri, C.F.; Rediguieri, C.F. A regulação de medicamentos no Brasil. 2013, Porto Alegre, Artmed, p. 97 – 110.
AVRAM, A.; GIOVANELLA, L.; GREENSPAN, B.; LOWSON, S. A.; LUSTER, M.; VAN NOSTRAND, D. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. The Journal of Nuclear Medicine, v. 63, n. 3, p. 15-35, 2022.
BORGES, Anne Karin da Mota et al. Câncer de tireoide no Brasil: estudo descritivo dos casos informados pelos registros hospitalares de câncer, 2000- 2016. Epidemiol. Serv. Saúde. v. 29, n. 4, e2019503, set. 2020. DOI: https://doi.org/10.5123/S1679-49742020000400012
BEM, G. T.; YEDDES, I.; MEDDEB, I. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer. Eur Arch Otolaryngol, v. 274, n. 2, p. 655-660, 2017. DOI: https://doi.org/10.1007/s00405-016-4111-5
VAN NOSTRAND, D.; NEUTZE, J.; ATKINS, F. Side Effects of “Rational Dose” Iodine-131 Therapy for Metastatic Well-Differentiated Thyroid Carcinoma. J. Nucl. Med. V. 27, n. 1, p. 1519-1527, 1986.
LIN, W. Y.; SHEN, Y. Y.; WANG, S. J. Short-Term Hazards of Low-Dose Radioiodine Ablation Therapy in Postsurgical Thyroid Cancer Patients. Clin. Nucl. Med, v. 21, n.1, p. 780-182, 1996. DOI: https://doi.org/10.1097/00003072-199610000-00006
KINUYA, S.; HWANG, E. H.; IKEDA, E.; YOKOYAMA, K.; MICHIGISHI, T.; TANOMI, N. Mallory-Weiss Syndrome Caused by Iodine-131 Therapy for Metastatic Thyroid Carcinoma. J. Nucl. Med, v.38, n.1, p. 1831, 1997.
IOD-IPEN-131. Elaine Bortoleti de Araújo. São Paulo: Centro de Radiofarmácia, IPEN, 2018. Bula de remédio.
CAPSION 50-3700 MBq (I-131) capsule, hard, 2018. Bula de remédio.
Sodium Iodine I 131 Capsule USP. Canada: Jubilant DraxImage Inc, 2011. Bula de remédio.
VALACHIS, A. A. High versus low radioiodine activity in patients with differentiated thyroid cancer: a meta-analysis. Acta Oncol. v. 52, n. 6, p. 1055- 1060, 2013. DOI: https://doi.org/10.3109/0284186X.2012.742959
JARZAB, B.; HANDKIEWICZ-JUNAK, D.; WLOCK, J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer, v. 12, n.1, p. 773-803, 2005. DOI: https://doi.org/10.1677/erc.1.00880
AUTTARA-ATTHAKORN, A.; SUNGMALA, J.; ANOTHAISINTWEE, T.; REUTRAKUL, S.; SRIPHRAPRADANG, C. Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials. Front Endocrinol (Lausanne). v. 29, n.13, p. 960-965, 2022. DOI: https://doi.org/10.3389/fendo.2022.960265
HORVATH, E.; SKOKNIC, V.; MAILIS, S.; TALA, H.; SILVA, C.; CASTILHO, E.; WHITTLE, C.; NIEDMANN, J. P.; GONZALEZ, P. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk. Thyroid. V. 30, n. 11, p. 1646-1655, 2020. DOI: https://doi.org/10.1089/thy.2019.0563
SCHROEDER, P. R.; HAUGEN, B. R.; PACINI, F.; REINERS, C.; SCHLUMBERGER, M.; SHERMAN, S. I.; COOPER, D. S., et al. Comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab, v. 91, n.3, p. 878-884, 2006. DOI: https://doi.org/10.1210/jc.2005-2064
Published
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Radiation Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
How to Cite
